Citicoline and Memory Function in Healthy Older Adults: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
5′-cytidine diphosphate choline
aging
brain
citicoline
memory loss
Journal
The Journal of nutrition
ISSN: 1541-6100
Titre abrégé: J Nutr
Pays: United States
ID NLM: 0404243
Informations de publication
Date de publication:
07 08 2021
07 08 2021
Historique:
received:
30
11
2020
revised:
08
01
2021
accepted:
05
04
2021
pubmed:
13
5
2021
medline:
29
1
2022
entrez:
12
5
2021
Statut:
ppublish
Résumé
Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. However, few studies have investigated its effect in healthy older populations. The objective of this study was to investigate the effects of citicoline (Cognizin®), on memory in healthy elderly populations with age-associated memory impairment (AAMI). A total of 100 healthy men and women aged between 50 and 85 y with AAMI participated in this randomized, double-blind, placebo-controlled trial. Participants were randomized to receive placebo (n = 51) or citicoline (n = 49; 500 mg/d) for 12 wk. Memory function was assessed at baseline and end of the intervention (12 wk) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, body weight, blood pressure, and hematology and metabolic panel. Intent-to-treat analysis was conducted using ANCOVA for the primary and secondary outcome variables with Bonferroni correction for multiple comparisons. A total of 99 out of 100 participants completed the study in its entirety. After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025). Composite memory (secondary outcome), calculated using the scores of 4 memory tests, also significantly improved to a greater extent following citicoline supplementation (mean: 3.78) compared with placebo (mean: 0.72, P = 0.0052). Dietary supplementation of citicoline for 12 wk improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. The findings suggest that regular consumption of citicoline may be safe and potentially beneficial against memory loss due to aging. This trial was registered at clinicaltrials.gov as NCT03369925.
Sections du résumé
BACKGROUND
Supplementation of citicoline (CDP-choline), a naturally occurring mononucleotide, has shown beneficial effects on memory function and behavior in populations with a wide range of impairments. However, few studies have investigated its effect in healthy older populations.
OBJECTIVE
The objective of this study was to investigate the effects of citicoline (Cognizin®), on memory in healthy elderly populations with age-associated memory impairment (AAMI).
METHODS
A total of 100 healthy men and women aged between 50 and 85 y with AAMI participated in this randomized, double-blind, placebo-controlled trial. Participants were randomized to receive placebo (n = 51) or citicoline (n = 49; 500 mg/d) for 12 wk. Memory function was assessed at baseline and end of the intervention (12 wk) using computerized tests (Cambridge Brain Sciences, Ontario, Canada). Safety measurements included adverse events query, body weight, blood pressure, and hematology and metabolic panel. Intent-to-treat analysis was conducted using ANCOVA for the primary and secondary outcome variables with Bonferroni correction for multiple comparisons.
RESULTS
A total of 99 out of 100 participants completed the study in its entirety. After the 12-wk intervention, participants supplemented with citicoline showed significantly greater improvements in secondary outcomes of episodic memory (assessed by the Paired Associate test), compared with those on placebo (mean: 0.15 vs. 0.06, respectively, P = 0.0025). Composite memory (secondary outcome), calculated using the scores of 4 memory tests, also significantly improved to a greater extent following citicoline supplementation (mean: 3.78) compared with placebo (mean: 0.72, P = 0.0052).
CONCLUSIONS
Dietary supplementation of citicoline for 12 wk improved overall memory performance, especially episodic memory, in healthy older males and females with AAMI. The findings suggest that regular consumption of citicoline may be safe and potentially beneficial against memory loss due to aging. This trial was registered at clinicaltrials.gov as NCT03369925.
Identifiants
pubmed: 33978188
pii: S0022-3166(22)00267-X
doi: 10.1093/jn/nxab119
pmc: PMC8349115
doi:
Substances chimiques
Cytidine Diphosphate Choline
536BQ2JVC7
Banques de données
ClinicalTrials.gov
['NCT03369925']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2153-2160Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.
Références
J Intern Med. 2017 Jan;281(1):65-74
pubmed: 27453565
Br J Nutr. 2013 Feb 14;109(3):511-9
pubmed: 22717142
JAMA. 1995 Sep 20;274(11):902-7
pubmed: 7674505
Int J Toxicol. 2009 Nov-Dec;28(6):479-87
pubmed: 19966140
Arzneimittelforschung. 1983;33(7A):1035-8
pubmed: 6684460
Annu Rev Psychol. 2002;53:1-25
pubmed: 11752477
Neurol Res. 1995 Aug;17(4):281-4
pubmed: 7477743
Am J Clin Nutr. 2011 Dec;94(6):1584-91
pubmed: 22071706
BMJ. 2020 Jun 26;369:m2269
pubmed: 32591407
J Am Geriatr Soc. 2012 Dec;60(12):2308-12
pubmed: 23110764
Environ Health Perspect. 2004 Mar;112(3):314-20
pubmed: 14998746
J Neurochem. 1995 Aug;65(2):889-94
pubmed: 7616250
Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4252-9
pubmed: 27036001
Annu Rev Nutr. 2006;26:229-50
pubmed: 16848706
Arzneimittelforschung. 1983;33(7A):1038-42
pubmed: 6684461
NMR Biomed. 2008 Nov;21(10):1066-75
pubmed: 18816480
Neurobiol Aging. 1998 Sep-Oct;19(5):437-45
pubmed: 9880046
Psychopharmacology (Berl). 2002 May;161(3):248-54
pubmed: 12021827
IUBMB Life. 2011 Sep;63(9):714-20
pubmed: 21818839
Ageing Res Rev. 2017 May;35:222-240
pubmed: 27713095
Psychol Aging. 2005 Mar;20(1):3-18
pubmed: 15769210
J Biol Chem. 2010 Aug 13;285(33):25382-93
pubmed: 20525991
Methods Find Exp Clin Pharmacol. 1999 Nov;21(9):633-44
pubmed: 10669911
Front Aging Neurosci. 2016 Sep 28;8:226
pubmed: 27733825
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD000269
pubmed: 15846601
AJNR Am J Neuroradiol. 2007 Feb;28(2):226-35
pubmed: 17296985
Ann Epidemiol. 2009 Nov;19(11):778-83
pubmed: 19656690
Psychopharmacology (Berl). 1996 Sep;127(2):88-94
pubmed: 8888372
Eur J Neurosci. 1997 Jul;9(7):1329-39
pubmed: 9240390
Front Behav Neurosci. 2013 Feb 01;7:2
pubmed: 23378831
Exp Biol Med (Maywood). 2006 May;231(5):490-504
pubmed: 16636297
Ann N Y Acad Sci. 1993 Sep 24;695:318-20
pubmed: 8239304
Arch Neurol. 1996 May;53(5):441-8
pubmed: 8624220
Brain. 2015 Feb;138(Pt 2):398-413
pubmed: 25524711
Methods Find Exp Clin Pharmacol. 1997 Apr;19(3):201-10
pubmed: 9203170
Clin Interv Aging. 2015 Sep 03;10:1421-9
pubmed: 26366063
J Atten Disord. 2019 Jan;23(2):121-134
pubmed: 26179181
Nutrients. 2020 May 07;12(5):
pubmed: 32392758
Acta Biomed. 2018 Jun 07;89(2):276-290
pubmed: 29957766
Stroke. 1999 Dec;30(12):2592-7
pubmed: 10582983